eZono appoints Cox CEO
This article was originally published in Clinica
Executive Summary
German tablet ultrasound system developer eZono has made ultrasound industry veteran Graham Cox CEO, effective 1 June. He will succeed co-founder and acting CEO Allan Dunbar, who will stay with the company as chief commercial officer. Mr Cox previously worked for another ultrasound specialist, SonoSite, for 13 years, most recently as vice-president, worldwide sales and distribution. SonoSite was acquired by Fujifilm in 2011 (www.clinica.co.uk, 15 December 2011). Before this, he had senior positions at ATL Ultrasound (which Philips acquired in 1998, www.clinica.co.uk, 3 August 1998) and Acuson (which Siemens acquired in 2000, www.clinica.co.uk, 2 October 2000). Privately-held eZono’s first-generation product, the eZono 3000, is CE marked for sale in Europe and gained US FDA 510(k) clearance in July 2011. The Jena-based firm’s ultrasound devices are aimed at the point-of-care market.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.